Physician profile
Jun Yang
NPI 1730166414
$10,268.72
in general payments reported to CMS, 2019-2025
34 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $932 · 2021: $1,576 · 2022: $1,619 · 2023: $1,689 · 2024: $1,718 · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,056.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,436.53 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,112.59 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $831.15 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Optinose US, INC. | $624.08 | 2019-2025 | |
| Genzyme Corporation | $553.97 | 2019-2025 | |
| Genentech USA, INC. | $530.87 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $406.57 | 2020-2025 | Hyqvia, Takhzyro, Cuvitru |
| Alk-Abello, INC | $395.38 | 2019-2024 | Grastek, Ragwitek, Odactra |
| Pfizer INC. | $332.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $315.09 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $268.06 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $201.46 | 2019-2023 | Airduo Digihaler |
| Ars Pharmaceuticals Operations, INC. | $179.96 | 2025 | Neffy |
| Grifols USA, LLC | $172.20 | 2019-2025 | Xembify |
| Kaleo, INC. | $120.27 | 2022-2024 | Auvi-Q |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $84.85 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.11 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $69.84 | 2021-2022 | |
| Bio Products Laboratory USA, INC. | $66.82 | 2019-2022 | |
| Amgen INC. | $62.23 | 2022-2024 | Tezspire |
| Biocryst US Sales Co., LLC | $61.22 | 2021-2025 | Orladeyo |
| Greer Laboratories, INC. | $59.69 | 2024-2025 | Oralair |
| Incyte Corporation | $42.74 | 2022 | |
| Shire North American Group INC | $39.48 | 2019 | |
| Circassia INC. | $31.91 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $29.31 | 2025 | Alvesco |
| Merck Sharp & Dohme LLC | $28.71 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $26.97 | 2019-2020 | |
| Allergan, INC. | $22.61 | 2020 | |
| Blueprint Medicines Corporation | $18.26 | 2023 | |
| Lilly USA, LLC | $17.62 | 2025 | Ebglyss |
| Organon LLC | $17.50 | 2025 | |
| Phadia US INC. | $16.64 | 2020 | |
| Horizon Therapeutics Plc | $15.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.